http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002081277-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55511 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55538 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-208 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 |
| filingDate | 2002-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bcc992fb66a17edc612f838c55075490 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed926d93cc0788cdaf019dfd06eea5ff http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55d0d044a6203ea2ef459d2fdd750dd1 |
| publicationDate | 2002-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2002081277-A1 |
| titleOfInvention | Methods and compositions for enhancing the immunostimulatory effect of interleukin-12 |
| abstract | Methods for enhancing the therapeutic and adjuvant use of IL- 12 by reducing unwanted transient immunosuppression caused by IL- 12 or by high doses thereof involve co-administering IL- 12 with an effective amount of an agent that inhibits or neutralizes nitric oxide (NO) in vivo. Enhanced vaccine therapy involves co-administering the IL- 12 adjuvant, a selected vaccine antigen and the NO inhibiting/neutralizing agent. Additionally, the toxicity of IL- 12 treatment may be reduced by co-administering IL- 12 with an effective amount of the NO inhibiting or neutralizing agent. A therapeutic composition characterized by reduced toxicity in mammals contains IL- 12, preferably a low dose thereof, and an NO inhibiting or neutralizing agent in a pharmaceutically acceptable carrier. A vaccine composition contains an effective adjuvanting amount of IL- 12, an effective amount of an NO inhibiting or neutralizing agent, and an effective protective amount of a vaccine antigen in a pharmaceutically acceptable carrier. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7850957-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004024132-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007224170-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009127669-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009127669-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2010214637-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004024132-A3 |
| priorityDate | 1998-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 331.